Drs. Verstovsek and Rafandi present data on Incyte’s JAK2 Inhibitor, INCB018424, currently being tested in MPD patients Dr. Tefferi presents research on JAK2 germline and survival in MF patients Favorable review of Cytopia by Mayo’s IRB and FDA for their JAK2 Inhibitor CYT387 trial now under way SBIO to present data on their JAK2 Inhibitor… Read More »ASH NEWS ON MYELOPROLIFERATIVE DISORDERS
The MPNRF Interferon (IFN) Initiative is a multi-center project that has brought together internationally recognized experts in both blood and solid tumors to determine how cytokine-driven pathways affect the trajectory of the MPNs, a closely-related group of progressive blood cancers. The collaboration among this group of scientists speaks to their drive to answer these questions: How… Read More »Interferon Initiative: we’re tackling the hard questions
According to a press release published by Constellation Pharmaceuticals, the latest findings in the Manifest Clinical Trial of CPI-0610 in Myelofibrosis Patients was found to have a profound effect on trial participants. The first four patients in the study, two of which are taking the therapy in combination with ruxolitinib, have shown potentially promising results such as,… Read More »PROMISING RESULTS RELEASED FROM CLINICAL TRIAL FOR MF PATIENTS
Today on the CBS program, “The Doctors,” Dr. Travis sits down with Matt, a polycythemia vera patient, and his physician Dr. Ellen Ritchie. In the segment, we learn about Matt’s experience with PV, his symptoms, and the NCCN Patient Guidelines for MPNs. The NCCN Patient Guidelines have proven very helpful for Matt. “Unfortunately, MPNs really… Read More »WHAT IS THIS RARE BLOOD CANCER THAT CAN CAUSE THE BLOOD TO THICKEN?
“Myeloproliferative neoplasms (MPNs) are still difficult to treat. A team from Vetmeduni Vienna and the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences/Medical University of Vienna has discovered a new therapeutic approach that could fundamentally change this situation, as evidenced by a study that was published recently in the academic journal Blood.”… Read More »MALIGNANT BONE MARROW DISEASE: NEW HOPE FOR MPN PATIENTS
“Abstract: Constitutive JAK2 signaling is central to myeloproliferative neoplasm (MPN) pathogenesis and results in activation of STAT, PI3K/AKT, and MEK/ERK signaling. However, the therapeutic efficacy of current JAK2 inhibitors is limited. We investigated the role of MEK/ERK signaling in MPN cell survival in the setting of JAK kinase inhibition. Type I and II JAK2 inhibition… Read More »TARGETING COMPENSATORY MEK/ERK ACTIVATION INCREASES JAK INHIBITOR EFFICACY IN MYELOPROLIFERATIVE NEOPLASMS.
In a press release published today, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has granted a Priority Review for Fedratinib, a possible new drug for the treatment of Myelofibrosis. “The acceptance of the NDA and granting of Priority Review for fedratinib represent the first potential new treatment option after many years for patients… Read More »U.S. FDA GRANTS PRIORITY REVIEW FOR FEDRATINIB – NEW DRUG APPLICATION IN MYELOFIBROSIS
oday is World Cancer Day, and we are using this day to kick off a month-long focus on patient advocacy, ending with Rare Disease Day on Wednesday, February 28th. Advocating on behalf of MPN patients is an important part of what the MPN Research Foundation does, and we are looking forward to growing this pillar… Read More »RARE DISEASE DAY 2019 KICKOFF
The MPN Research Foundation is doing our part to advocate for the MPN patient population. The needs of patients are first and foremost in our minds when we choose what researchers to support, have conversations with the FDA, and raise awareness about these rare blood cancers. There are so many ways you can support our… Read More »ARE YOU READY TO ROLL UP YOUR SLEEVES?
Breaking news on ropeginterferon for PV patients. In December of 2018, we shared the news that CHMP (The Committee for Medicinal Products for Human Use; European Medicines Agency’s committee responsible for elaborating the agency’s opinions on all issues regarding medicinal products for human use) gave a positive opinion on ropeginterferon and recommended granting market authorization in the… Read More »BREAKING NEWS ON ROPEGINTERFERON FOR PV PATIENTS
